Dermatofibrosarcoma protuberans: An analysis of proliferative activity, DNA flow cytometry and p53 overexpression with emphasis on its progression

Pathology International

Volumn 49, Issue 9, 1999, Pages 799-806

  Sasaki, Manabu ^a,b   Ishida, Tsuyoshi ^c   Horiuchi, Hajime ^c   Machinami, Rikuo ^c  

^a Yaizu Municipal Hospital   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c NONE

Author keywords

Aneuploidy; Dermatofibrosarcoma protuberans; Fibrosarcomatous dermatofibrosarcoma protuberans; p53 overexpression; Proliferative activity; Tumor progression

Indexed keywords

PROTEIN P53;

ADOLESCENT; ADULT; ARTICLE; DERMATOFIBROSARCOMA PROTUBERANS; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; ANEUPLOIDY; ANTIGENS, NUCLEAR; CELL DIVISION; DERMATOFIBROSARCOMA; DISEASE PROGRESSION; DNA, NEOPLASM; FEMALE; FIBROSARCOMA; FLOW CYTOMETRY; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NUCLEAR PROTEINS; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032693689     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.1999.00944.x     Document Type: Article

References (41)

1. 1 Enzinger FM, Weiss SW. Fibrohistiocytic tumors of intermediate malignancy. In: Soft tissue tumors, 3rd edn. Mosby, St Louis, 1994; 325-337.
2. 2 Wrotnowski U, Cooper PH, Shmookler BM. Fibrosarcomatous change in dermatofibrosarcoma protuberans. Am. J. Surg. Pathol. 1988; 12: 287-293.
3. 3 Ding J, Hashimoto H, Enjoji M. Dermatofibrosarcoma protuberans with fibrosarcomatous areas: A clinicopathological study of nine cases and a comparison with allied tumors. Cancer 1989; 64: 721-729.
4. 4 Connelly JH, Evans HL. Dermatofibrosarcoma protuberans: A clinicopathologic review with emphasis on fibrosarcomatous areas. Am. J. Surg. Pathol. 1992; 16: 921-925.
5. 5 O'Connell JX, Trotter MJ. Fibrosarcomatous dermatofibrosarcoma protuberans: A variant. Mod. Pathol. 1996; 9: 273-278.
6. 6 Morimitsu Y, Hisaoka M, Okamoto S, Hashimoto H, Ushijima M. Dermatofibrosarcoma protuberans and its fibrosarcomatous variant with areas of myoid differentiation: A report of three cases. Histopathology 1998; 32: 547-551.
7. 7 Mentzel T, Beham A, Katenkamp D, Dei Tos AP, Fletcher CDM. Fibrosarcomatous ('high-grade') dermatofibrosarcoma protuberans. Clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am. J. Surg. Pathol. 1998; 22: 576-587.
8. 8 Hisaoka M, Okamoto S, Morimitsu Y, Tsuji S, Hashimoto H. Dermatofibrosarcoma protuberans with fibrosarcomatous areas. Molecular abnormalities of the p53 pathway in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Virchows Arch. 1998; 433: 323-329.
9. 9 Yokoe T, Izuo M, Ishida T, Iino Y, Kawai T. DNA ploidy and S-phase fraction as prognostic factors in breast cancer. Jpn J. Surg. 1990; 20: 491-497.
10. 10 Fontanini G, Pingitore R, Bigini D et al. Growth fraction in non-small cell lung cancer estimated by proliferating cell nuclear antigen and comparison with Ki-67 labeling and DNA flow cytometry data. Am. J. Pathol. 1992; 141: 1285-1290.
11. 11 Kamel OW, LeBrun DP, Davis RE, Berry GJ, Warnke RA. Growth fraction estimation of malignant lymphomas in formalin-fixed paraffin-embedded tissue using anti-PCNA/Cyclin 19A2. Am. J. Pathol. 1991; 138: 1471-1477.
12. 12 Nigro JM, Baker SJ, Preisinger AC et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 34: 705-707.
13. 13 Stratton MR, Moss S, Warren W. Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RBI gene. Oncogene 1990; 5: 1297-1301.
14. 14 Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK. Mechanisms of p53 loss in human sarcomas. Proc. Natl Acad. Sci. USA 1990; 87: 5863-5867.
15. 15 Soini Y, Vahakangas K, Nuorva K, Kamel D, Lane DP, Paakko P. p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumors. J. Pathol. 1992; 168: 29-33.
16. 16 Schutte B, Reynders MMJ, Bosman FT, Blijham GH. Flow cytometric determination of DNA ploidy level in nuclei isolated from paraffin-embedded tissue. Cytometry 1985; 6: 26-30.
17. 17 Vindelφv LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983; 3: 323-327.
18. 18 Tagawa Y, Nakazaki T, Yasutake T, Matsuo S, Tomita M. Comparison of pepsin and trypsin digestion on paraffin-embedded tissue preparation for DNA flow cytometry. Cytometry 1993; 14: 541-549.
19. 19 Swanson SA, Brooks JJ. Proliferation markers Ki-67 and p105 in soft tissue lesions: Correlation with DNA flow cytometric characteristics. Am. J. Pathol. 1990; 137: 1491-1500.
20. 20 Ooe M, Nogita T, Kawashima M. Comparative study of Ki-67 immunostaining and nuclear DNA content in histiofibrous tumors. J. Dermatol. 1992; 19:12-18.
21. 21 Mazerolles C, Rishmann P, Chopin D et al. Usefulness of MIB 1 monoclonal antibody in assessing the proliferative index in human bladder carcinoma: comparison with Ki-67 antibody. Histopathology 1994; 25: 563-568.
22. 22 Oshiro Y, Fukuda T, Tsuneyoshi M. Atypical fibroxanthoma versus benign and malignant fibrous histiocytoma: a comparative study of their proliferative activity using MIB-1, DNA flow cytometry, and p53 immunostaining. Cancer 1995; 75: 1128-1134.
23. 23 Ljungberg B, Stenling R, Roos G. DNA content in renal cell carcinoma with reference to tumor heterogeneity. Cancer 1985; 56: 503-508.
24. 24 Ishii T, Koide O. An autopsy case of metastasizing protuberant dermatofibrosarcoma, Acta Pathol. Jpn 1975; 25: 503-515.
25. 25 Xiang J, Spanier SS, Benson NA, Braylan RC. Flow cytometric analysis of DNA in bone and soft-tissue tumors using nuclear suspensions. Cancer 1987; 59: 1951-1958.
26. 26 Kreicsbergs A, Tribukait B, Willems J, Bauer HCF. DNA flow analysis of soft tissue tumors. Cancer 1987; 59: 128-133.
27. 27 Radio SJ, Wooldridge TN, Linder J. Flow cytometric DNA analysis of malignant fibrous histocytoma and related fibrohistiocytic tumors. Hum. Pathol. 1988; 19: 74-77.
28. 28 Matsuno T, Gebhardt MC, Schiller AL, Rosenberg AE, Mankin HJ. The use of flow cytometry as a diagnostic aid in the management of soft-tissue tumors. J. Bone Joint Surg. 1988; 70: 751-760.
29. 29 El-Nagger AK, Ro JY, Ayala AG, Hinchey WW, Abdul-Karim FW, Batsakis JG. Angiomatoid malignant fibrous histiocytoma: flow cytometric DNA analysis of six cases. J. Surg. Oncol. 1989; 40: 201-204.
30. 30 Kroese MCS, Rutgers DH, Wils IS, Van Unnik JAM, Roholl PJM. The relevance of the DNA index and proliferation rate in the grading of benign and malignant soft tissue tumors. Cancer 1990; 65: 1782-1788.
31. 31 Van den Berg E, Van Oven MW, De Jong B et al. Comparison of cytogenetic abnormalities and deoxyribonucleic acid ploidy of benign, boderline malignant, and different grades of malignant soft tissue tumors. Lab. Invest. 1994; 70: 307-313.
32. 32 Oshiro Y, Fukuda T, Tsuneyoshi M. Fibrosarcoma versus fibromatoses and cellular nodular fasciitis: a comparative study of their proliferative activity using proliferating cell nuclear antigen, DNA flow cytometry and p53. Am. J. Surg. Pathol. 1994; 18: 712-719.
33. 33 Alvarez-Canas MC, Mayorga M, Fernandez F et al. Dermatofibrosarcoma protuberans of the vulva: clinico- pathological, immunohistochemical and flow cytometric study of a case. Acta Obstet. Gynecol. Scand. 1996; 75: 82-85.
34. 34 Collin F, Chassevent A, Bonichon F, Bertrand G, Terrier P, Coindre J-M. Flow cytometric DNA content analysis of 185 soft tissue neoplasms indicates that S-phase fraction is a prognostic factor for sarcoma. Cancer 1997; 79: 2371-2379.
35. 35 Huuhtanen RL, Blomqvist CP, Wiklund TA et al. S-phase fraction of 155 soft tissue sarcomas: correlation with clinical outcome. Cancer 1996; 77: 1815-1822.
36. 36 Kallioniemi O-P, Punnonen R, Mattila J, Lehtinen M, Koivula T. Prognostic significance of DNA index, multiploidy, and S-phase fraction in ovarian cancer. Cancer 1988; 61: 334-339.
37. 37 Dei Tos AP, Doglioni C, Laurino L, Barbareschi M, Fletcher COM. p53 protein expression in non-neoplastic lesions and benign and malignant neoplasms of soft tissue. Histopathology 1993; 22: 45-50.
38. 38 Toguchida J, Yamaguchi T, Ritchie B. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res. 1992; 52:6194-6199.
39. 39 Eriksson ET, Schimmelpenning H, Aspenblad U, Zetterberg A, Auer GU. Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease. Hum. Pathol. 1994; 25: 1228-1233.
40. 40 Visakorpi T, Kallioniemi O-P, Heikkinen A, Koivula T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinoma defined by p53 accumulation. J. Natl Cancer Inst. 1992; 84: 883-887.
41. 41 Drobnjak M, Latres E, Pollack D et al. Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J. Natl Cancer Inst. 1994; 86: 549-554.